Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04273594 · ClinicalTrials.gov registry record · NA
FemBloc® Permanent Contraception - Confirmation Feasibility Trial
A NA study of Contraception, sponsored by Femasys.
- Active
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 6
- Study locations
NCT04273594: Active NA study of Contraception, sponsored by Femasys.
NCT04273594 is a NA study of Contraception that is active but no longer recruiting, run by Femasys. The registered enrollment target is 45 participants, below the 454-participant average among 72 other Contraception trials with a reported enrollment target (90% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04273594, a NA study of Contraception, is active but no longer recruiting, sponsored by Femasys.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 6
- Study locations
Study Summary
The trial objectives include evaluating the adequacy of proposed mitigations for the previous pivotal trial of the FemBloc Permanent Contraceptive System and validating the confirmation procedure by comparing FemChec (ultrasound) to fluoroscopic hysterosalpingogram (fluoro HSG) for post-occlusion in the same patient.
Primary Outcome
Number of subjects told to rely divided by number of qualified subjects
Conditions Studied
Interventions
- DEVICE FemBloc
Study Locations (6)
Arizona
- New Horizons Clinical Trials - Chandler
- Precision Trials AZ, LLC - Phoenix
Georgia
- Midtown OB GYN North - Columbus
Indiana
- Women's Health Advantage - Fort Wayne
Michigan
- Saginaw Valley Medical Research Group - Saginaw
Ohio
- University Hospitals - Cleveland Medical Center - Beachwood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2020-02-27 |
| Est. Completion | 2027-04 |
| Phase | NA |
What the registry record for NCT04273594 still lists
NCT04273594 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 454-participant average among 72 other Contraception trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Contraception appearing as the primary indexed condition, and to 1 intervention - of which FemBloc is the first listed.
NCT04273594 lists 6 locations in 5 states (Arizona, Georgia, Indiana).
Frequently Asked Questions
What is clinical trial NCT04273594 about?
NCT04273594 is a clinical study titled "FemBloc® Permanent Contraception - Confirmation Feasibility Trial". The trial objectives include evaluating the adequacy of proposed mitigations for the previous pivotal trial of the FemBloc Permanent Contraceptive System and validating the confirmation procedure by comparing FemChec (ultrasound) to fluoroscopic hysterosalpingogram (fluoro HSG) for post-occlusion in...
What is the current status of trial NCT04273594?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 45 participants. The study started on 2020-02-27. Estimated completion is 2027-04.
What conditions does trial NCT04273594 study?
This clinical trial studies the following conditions: Contraception.
What interventions are being tested in trial NCT04273594?
The interventions under investigation include: FemBloc (DEVICE).
Who is sponsoring clinical trial NCT04273594?
This trial is sponsored by Femasys, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04273594 being conducted?
This trial has 6 study locations across Arizona, Georgia, Indiana, Michigan, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contraception
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04273594's enrollment target sits among peer trials
45 54th of 72 higher than 19 of 72 other Contraception trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Contraception trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Patient-clinical Linkages to Improve Trust and Engagement in Postpartum Healthcare
RECRUITING · NA
-
Empathy Through Pain Control: Lidocaine Paracervical Block for IUD Placements
RECRUITING · NA
-
Hormonal Contraception Access Through Pharmacist Prescribing Implementation
RECRUITING · NA
-
Prospective Multi-Center Trial for FemBloc Permanent Birth Control
RECRUITING · NA
-
Contraceptive Efficacy Study of Ovaprene
RECRUITING · NA
-
Intervening on Women's Health for Rural Young Cancer Survivors
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI